WHITE OAK, MD – JULY 20: A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Photo by Sarah Silbiger/Getty Images)
Getty Images
There are millions of people worldwide living with mitochondrial diseases. These are inherited conditions that make it difficult for the body’s cells to produce energy. Patients have traditionally had limited options beyond treatments that help with symptoms. However, a new drug has recently been approved that targets the root cause of certain mitochondrial diseases. This breakthrough offers hope to many families and signifies a new direction for future treatments.
Understanding Mitochondrial Disease
Mitochondrial diseases arise when an individual’s genes cause issues in the mitochondria, which are the cells’ power plants. When the mitochondria cannot function properly, the body lacks sufficient energy, resulting in symptoms like fatigue, weakness, dizziness, and various health problems affecting muscles, brain, heart, hearing, or vision. Mitochondrial diseases encompass a range of conditions, with symptoms manifesting at different ages. While some individuals can lead relatively normal lives, others, especially young children, may experience rapid deterioration, posing life-threatening risks.
One of the rarest and most severe forms of mitochondrial disease is thymidine kinase 2 deficiency. Children with this condition may initially achieve developmental milestones but regress over time, requiring assistance from medical devices. Frequent hospital visits become routine, and without intervention, some children may not survive beyond a few years.
Historically, medical care for mitochondrial diseases has focused on supportive measures such as supplements, vitamins, and physical therapy to help individuals maintain their strength and overall health. As the disease progresses, some patients may necessitate feeding tubes or respiratory support. While these interventions can alleviate symptoms, they do not address the underlying cellular issue. Consequently, many families have witnessed their loved ones’ health deteriorate despite the best available care.
Breakthrough in Clinical Trials
In November 2025, the FDA granted approval for a therapy targeting a rare mitochondrial disease. The medication, known as KYGEVVI, stands out from previous treatments by directly addressing the genetic malfunction instead of solely alleviating symptoms. This innovative drug combines two compounds essential for DNA and nucleic acid synthesis, compensating for the cellular defect and restoring proper mitochondrial function.
Clinical studies involving children and adults receiving this therapy have reported improvements in strength, respiratory function, and swallowing abilities. Patients on KYGEVVI experienced reduced infection rates and decreased hospital stays. Some individuals even regained lost motor skills, enhancing their independence and quality of life. The majority of patients encountered only minor side effects, primarily gastrointestinal discomfort that was easily manageable. Importantly, the benefits of the drug persisted over several years, preserving the enhanced abilities and strength in most patients.
Implications for Rare Disease Treatment Advancements
This milestone represents one of the initial medications capable of repairing mitochondrial DNA in patients, demonstrating tangible outcomes in individuals rather than just in laboratory animals. Moreover, this approval marks a significant advancement for individuals with rare diseases, signaling the feasibility of developing new therapies for these conditions and fostering optimism for future treatments. The success of this breakthrough could attract more funding and research focus, facilitating the discovery of improved solutions for individuals with diverse mitochondrial disorders.
Progress is already underway in the field, building on the recent FDA approval of elamipretide for Barth syndrome. Other experimental drugs, including sonlicromanol and KL1333, are advancing treatment for related mitochondrial disorders and DNA depletion syndromes. The efficacy of these therapies is fostering hope and investment, marking the dawn of a new era in mitochondrial medicine.
Future Directions in Rare Disease Research
The horizon for mitochondrial disease and other rare disorders holds significant potential. To sustain progress, upcoming treatments must prioritize patients’ real needs, focusing on enhancing their quality of life. The recent approval of KYGEVVI signifies tangible positive change, offering a glimpse of a brighter future for individuals grappling with mitochondrial diseases. With increased support and collaborative efforts, the outlook for those affected by these conditions could significantly improve.
Correction, November 14, 2025: This article has been updated to clarify that KYGEVVI is among the first therapies targeting mitochondrial DNA repair, not the first. Elamipretide (Forzinity) received FDA approval in September 2025 as the first therapy targeting mitochondrial function.
